Slide 1: Fourth Quarter and Year-End 2022 Financial Results & Business Update
Fourth Quarter and Year-End 2022 Financial Results & Business Update February 16, 2023 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Investor Relations & Corporate Affairs Q4 & FY 2022 Commercial Review Todd Nichols, Chief Commercial Officer Q4 & FY 2022 Financial Results; 2023 Financial Expectations; Updated Profitability Targets Iain Brown, Chief Financial Officer 2023 Outlook; Update on P
Slide 4: 2022 Commercial Review
2022 Commercial Review
Slide 5: Topline Growth and Diversification Reflect Evolving Business
Topline Growth and Diversification Reflect Evolving Business *Inclusive of ARISTADA INITIO® **Licensed product (royalty & manufacturing revenue) Key Product Revenues ($M)
Slide 6: LYBALVI Prescription Growth Trends
LYBALVI® Prescription Growth Trends *Source: IQVIA NPA Weekly Q4’22 total TRx: ~28,400 reflecting 23% sequential growth compared to Q3’22 ~7,600 prescribers had written a prescription for LYBALVI (as of 12/31/22) since launch reflecting 27% increase since Q3’22 Post-Launch TRx by Week* (Through 2/3/
Slide 7: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations *These expectations are provided by the Company on Feb. 16, 2023 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. LYBALVI Quarterly Net Sales ($M) Q4’22 net sales of $34.9M reflect 2
Slide 8: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales ($M)* Q4’22 year-over-year net sales increased 1% to $79.2M FY’22 year-over-year net sales increased 10% to $302.1M Gross-to-net deductions: 54.2% in FY’22, compared to 53.7% in FY’21 Outlook: FY’23 net sales expected to range from
Slide 9: ARISTADA Prescription Growth Trends
ARISTADA® Prescription Growth Trends ARISTADA Quarterly TRx MOT* Q4’22 year-over-year growth of 7% on TRx months of therapy (MOT) basis Market Share: TRx MOT: 10% of atypical LAI market prescriptions in Q4’22 *Source: IQVIA NPA
Slide 10: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations *These expectations are provided by the Company on Feb. 16, 2023 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. VIVITROL Quarterly Net Sales ($M) Q4’22 year-over-year net sales in
Slide 11: Q4 & FY 2022 Financial and Operational Performance
Q4 & FY 2022 Financial and Operational Performance
Slide 12: FY 2022 Financial Results Summary
In millions FY 2022 Financial Results Summary** Total Revenue In millions GAAP Net Loss In millions Non-GAAP Net Income* *Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. **In FY22, royalty rev
Slide 13: Q4 2022 Revenue Summary
Q4 2022 Revenue Summary Amounts in the table above may not sum due to rounding. *Inclusive of ARISTADA INITIO® **In Q4'22, royalty revenues from long-acting INVEGA products were $25.2 million, compared to $81.1 million in Q4’21. This decrease was driven by Janssen’s partial termination of the licens
Slide 14: 2022 Revenue Summary
2022 Revenue Summary Amounts in the table above may not sum due to rounding. *Inclusive of ARISTADA INITIO® ** In FY22, royalty revenues from long-acting INVEGA products were $115.7 million, compared to $303.1 million in FY21. This decrease was driven by Janssen’s partial termination of the license
Slide 15: Alkermes: 2023 Financial Expectations
Alkermes: 2023 Financial Expectations* *These expectations are provided by the Company on Feb. 16, 2023 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconciliation of these non-GAAP financial measures to the most di
Slide 16: 2023 Financial Expectations Breakdown
2023 Financial Expectations* Breakdown *These expectations, provided by the Company on Feb. 16, 2023 and effective only as of such date, reflect the mid-points within the ranges of 2023 guidance provided by the Company on Feb. 16, 2023 and are intended to provide a framework for understanding the co
Slide 17: Updated Profitability Targets Reflect One-Year Acceleration of Previously Provided Targets
Updated Profitability Targets Reflect One-Year Acceleration of Previously Provided Targets *The Company is not providing reconciliations of, or comparable GAAP measures for, forward-looking non-GAAP profitability targets because the comparable GAAP measures are not determinable without unreasonable
Slide 18: 2023 Outlook & Planned Separation Update
2023 Outlook & Planned Separation Update
Slide 19: Clear Priorities to Unlock Value in 2023
Clear Priorities to Unlock Value in 2023 2023 Business Priorities and Value Drivers Drive launch of LYBALVI® Continued execution of commercial strategy and investment in DTC campaign Advance orexin 2 receptor agonist Establish initial safety and tolerability profile and generate initial clinical pro
Slide 20: Post-Separation Alkermes: Pure-Play, Commercial-Stage Neuroscience Company
Post-Separation Alkermes* Pure-Play, Commercial-Stage Neuroscience Company Separation expected to enhance profitability Builds on Alkermes’ innovation and excellence in neuroscience *Assuming separation of the Company’s oncology business is effected through a spin-off of the oncology business into a
Slide 21: Appendix
Appendix Confidential, Internal Use Only
Slide 22: Appendix: Financial Results GAAP to Non-GAAP Adjustments
Appendix: Financial Results GAAP to Non-GAAP Adjustments Amounts in the table above may not sum due to rounding.
Slide 23: Appendix: 2023 Guidance GAAP to Non-GAAP Adjustments
Appendix: 2023 Guidance GAAP to Non-GAAP Adjustments Projected GAAP and non-GAAP measures reflect the mid-points within the Company’s financial expectations ranges. +2023 per share expectations are calculated based on a weighted average basic share count of approximately 166.5 million shares outstan
Slide 24: www.alkermes.com
www.alkermes.com